Curis vs Relay Therapeutics
CRIS and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and RLAY compare
Relay Therapeutics is the larger company, worth 4262 times as much as Curis ($4.0B against $930K).
Relay Therapeutics scores higher on the StockData Score (10 against 5 for Curis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | RLAY |
|---|---|---|
| Size and price | ||
| Market cap | $930K | $4.0B |
| Share price | $0.445 | $18.09 |
| Change, 1 year | −98.2% | 193% |
| Change, 5 years | −100.0% | −47.5% |
| Beta (5Y) | 1.90 | 1.94 |
| Employees | 24 | 192 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 383× |
| P/B | 0.4× (better) | 4.8× |
| Growth | ||
| Revenue growth (TTM) | – | 23.9% |
| Revenue growth, 5Y average | −2.7% (better) | −28.6% |
| Profitability | ||
| Operating margin | – | −3095% |
| Net margin | – | −2837% |
| Return on equity | – | −41.2% |
| Return on invested capital | – | −41.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.43 | 14.62 (better) |
| Altman Z-score | −98.36 | 25.18 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.1% | 113% |
| Held by insiders | 20.4% | 24.5% |
| Insider net buying, 12 months | $5.5K (better) | −$129M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 61.8% | 26.4% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.